Heart Transplant Failure and Rejection
16
3
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
Allograft Dysfunction in Heart Transplant
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
Brazilian Clinical Registry of Heart Transplantation
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
Heart TIMING - Heart Transplantation IMagING
Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation